Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing
AuthorsWillig, James H.
Westfall, Andrew O.
Mugavero, Michael J.
Allison, Jeroan J.
Paz, Jorge III
Saag, Michael S.
UMass Chan AffiliationsDepartment of Quantitative Health Sciences
Document TypeJournal Article
Dose-Response Relationship, Drug
Drug Administration Schedule
Health Services Research
MetadataShow full item record
AbstractBACKGROUND: Whereas access to antiretroviral therapy (ART) for HIV-infected individuals in the developing world is increasing, data on factors impacting initial regimen durability are lacking. METHODS: Retrospective review patients starting initial ART at Instituto de Medicine Tropical (Lima, Peru) April 1, 2004 to December 30, 2007. Survival methods (Kaplan-Meier, Cox proportional hazard) assessed factors associated with regimen durability including an interaction term between nucleoside reverse transcriptase inhibitor backbone and time. RESULTS: Decreased initial regimen durability was observed with weight <60 kg [hazards ratio (HR) = 1.77; 95% confidence interval (CI) = 1.25-2.51], CD4 <200 (HR = 1.73; 95% CI = 1.03-2.91), and zidovudine (AZT) use at <120 days (HR = 2.09; 95% CI = 1.22-3.57). In contrast, after 120 days, AZT use decreased risk of discontinuation (HR = 0.52; 95% CI = 0.28-0.95). Early (<120 days) toxicity-related discontinuation of AZT containing regimens was observed in 44% of patients <50 kg at baseline vs. 14% of those >70 kg. An increased risk of early toxicity-related discontinuation of AZT-containing regimens was observed for baseline weight <60 kg (HR = 2.52; 95% CI = 1.46-4.35). CONCLUSIONS: Lower baseline weight and lower CD4 values at ART initiation were associated with decreased regimen durability. Compared with didanosine/stavudine, AZT use initially increased, then subsequently (>120 days) lowered hazards for regimen discontinuation. Weight <60 kg was associated with an increased risk of toxicity-related AZT discontinuation. As ART use expands globally, further study into maximally durable, least toxic regimens, and the role of weight-based AZT dosing is imperative.
SourceJ Acquir Immune Defic Syndr. 2010 Feb 1;53(2):215-21. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/47720
Related ResourcesLink to Article in PubMed